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Abstract The cytotoxic effect of Shiga-like toxin (Stx;
produced by certain Escherichia coli strains) plays a central
role in typical hemolytic uremic syndrome (HUS). It
damages the renal endothelium by inhibiting the cellular
protein synthesis. Also, the monocyte has a specific
receptor for Stx but is not sensitive for the cytotoxic effect.
In this work, monocytes were studied as a potential
transporter for Stx to the renal endothelium. Coincubation
of isolated human monocytes loaded with Stx and target
cells (vero cells and human umbilical vascular endothelial
cells) were performed. Transfer was determined by mea-
suring the protein synthesis of target cells and by flow
cytometry. Furthermore, the effect of a temperature shift on
loaded monocytes was investigated. Stx-loaded monocytes
reduced the protein synthesis of target cells. After adding an
antibody against Stx, incomplete recovery occurred. Also,
adding only the supernatant of coincubation was followed
by protein synthesis inhibition. Stx detached from its
receptor on the monocyte after a change in temperature,
and no release was detected without this temperature shift.
Although the monocyte plays an important role in the




Hemolytic uremic syndrome (HUS) is a clinical syndrome
consisting of three characteristic features: hemolytic ane-
mia, thrombocytopenia, and acute renal failure [1]. In the
new classification of HUS, infections due to Shiga-like
toxin (Stx)-producing bacteria belong to the category
“etiologically advanced” [2]. This work focuses on the
form in which Stx-producing Escherichia coli is the most
common pathogen [1]. It can produce several types of Stx,
of which Stx1, Stx2, and Stx2c are most frequently
associated with HUS [3, 4]. Stx plays a crucial role in the
pathogenesis because of its cytotoxic effect on the renal
endothelium. Both renal tubular epithelial cells and glo-
merular visceral epithelial cells (podocytes) are also
sensitive to the toxic effect of Stx [5, 6]. It can inhibit the
protein synthesis of these cells after specifically damaging
the ribosomal RNA [7]. However, the question of how this
toxin is targeted mainly to the kidney remains unsolved. Stx
was never detected in the serum of patients, but it was
detected in renal biopsy material of patients with HUS [8].
As a specific treatment for HUS is still lacking, more
insight into the transport of this toxin might lead to new
intervention strategies.
After oral ingestion of the bacteria through contaminated
food or water, the noninvasive bacteria adhere to the
intestinal epithelial cells of the distal small bowel and
colon. This leads to a rearrangement of the morphology of
the cells and initiates inflammation [9, 10]. Bacterial
flagellin plays an important role in this process [11]. Stx
can probably reach the circulation because of active
transport in these cells and also passively after damage to
the intestinal cells [12]. Subsequently, it has to be trans-
ported in the circulation to reach its primary target, the renal
endothelium.
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carrier for the toxin. Stx can bind to a specific receptor,
which is a globotriaosylceramide (Gb3, P
k Antigen,
CD77) [13]. This receptor is present on renal endothelial
cells but also on blood cells. Stx binding has been described
on red blood cells [14], B lymphocytes [15], and platelets,
which also have an additional binding possibility (glyco-
lipid, band 0.03) [16]. Several groups showed the existence
of a specific binding of Stx on monocytes [17, 18, 19].
After binding to its receptor, Stx can be internalized.
Whereas in epithelial cells the toxin follows the retrograde
transport route and becomes cytotoxic, in monocytes it is
targeted to the lysosomes and will get degraded [19].
During this transport, the monocyte becomes activated.
This will lead to an increase of transcription factors, such as
nuclear factor kappa B (NF-κB) and activator protein 1
(AP-1), and an upregulated production of cytokines such as
interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6,
and IL-8 [17, 20]. These events will have a pro-inflamma-
tory effect.
We postulated that, as the monocyte has a specific
receptor, it might also function as a carrier to transport Stx
to the renal endothelium. To investigate this hypothesis, Stx
was loaded to isolated monocytes from healthy donors and
coincubated with target cells [vero cells and human
umbilical cord venous endothelial cells (HUVEC)]. The
level of transfer was determined by measuring the protein
synthesis of these target cells and the transfer of fluorescein




Stx2 was kindly provided by Dr. M. Karmali (Public Health
Agency of Canada, Ontario, Canada). FITC-labeled Stx1B
subunit and
125I-Stx1B subunit were a gift from Dr. L.
Johannes (Institut Curie, Paris, France). Stx1B subunit is a
useful tool for studying binding in monocytes [19]. It is the
binding part of the toxin, whereas the enzymatic A subunit
will only stimulate the uptake of the toxin and does not
affect binding [21]. Vero cell medium consists of M199
(Gibco; Paisley/UK), fetal calf serum (FCS, Greiner Bio-
One; Kremsmunster/Austria), penicillin/streptomycin
(Gibco, Paisley/UK), and glutamine (MP Biomedicals;
Eschwege/Germany). HUVEC medium is made of M199,
human serum (HS; Cambrex; Walkersville/USA), newborn
calf serum (NBCS; Gibco, Paisley/UK), penicillin/strepto-
mycin, glutamine, heparine (Leo Pharma BV, Breda/The
Netherlands), and endothelial-cell growth factor [22].
Ethylenediamine tetraacetic acid (EDTA) tubes were
purchased from BD Vacutainer (Alphen aan de Rijn/The
Netherlands). The MACS kit for negative selection of
monocytes was provided by Miltenyi Biotec (Bergisch
Gladbach/Germany). Hank’s balanced salt solution (HBSS)
was ordered from MP Biomedicals (Eschwege/Germany).
Human serum albumin (HSA) from Sanquin (Amsterdam/
The Netherlands) and porcine gelatin from Fluka (Neu-
Ulm, Germany) was used. Trichloroacetic acid and TNF-α
was obtained from Sigma-Aldrich Chemie B.V. (Zwijn-
drecht/The Netherlands). The antibody against Stx2 (TMA-
15) is well characterised [23]. It was a kind gift from Dr.
Yamagami from the Department of Biomedical Research
from the Teijin Institute, Tokyo, Japan.
3H-leucine and
Ficoll-paque PLUS was purchased from Amersham Bio-
sciences (Uppsala, Sweden). Culture plates were ordered
from Corning Inc. (Corning, USA).
Culture of vero cells and HUVEC
Vero cells (renal epithelial cells of the African green
monkey) were grown to confluency on 24-well plates
(ordered from ATCC; Middlesex, UK). These cells have a
high basal expression of Stx-receptor CD77. HUVEC were
isolated, and these cells were grown to confluence on
gelatin-coated 24-well plates [24]. Every 2 days, fresh
medium was added to the cells. In contrast, HUVEC were
preincubated for 24 h with TNF-α (10 ng/ml) to upregulate
the expression of CD77.
Isolation of monocytes and loading with Stx2
Fresh venous blood (20 ml) from 40 healthy donors was
collected into EDTA tubes. Monocytes were isolated by
negative selection using antibody-labeled beads (CD3,
CD7, CD16, CD56, and CD123). After centrifugation of
blood over Ficoll (20 min 400 g without break at room
temperature), the interphase (containing monocytes, lym-
phocytes, and platelets) was collected. Platelets were
removed by centrifugation (200 g 10 min at room
temperature) before adding the beads. The purity of
monocytes after the magnetic isolation was (as determined
by flow cytometry) 80–85%. After the isolation, the
monocytes were resuspended in HBSS with 1% HSA and
placed on ice. In every experiment, monocytes from one
donor were used. To load the monocytes with Stx2, the
toxin was added to a concentration of 10 nM during a time
period of 3 h [17]. The cells remained on ice. After proper
washing to remove all unbound Stx2, the cells were
resuspended in vero cell or HUVEC medium (in which
HS and NBCS were substituted by FCS). Monocytes stayed
viable after this loading, as determined by trypan blue
exclusion.
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These experiments were performed in two different
experimental settings: with transfer of loaded monocytes
from 4° to 37°, and without change of temperature. To
start with the first setting, the Stx2-loaded monocytes
were added to a monolayer of target cells [HUVEC (n=
10) or vero- cells (n=9)] in a concentration of 1×10
6 per
well. This was performed during 24 h at 37°C. For
comparison, also monocytes without Stx were used. To
determine the specificity of the effect of Stx2, the loaded
monocytes were preincubated with a well-characterized
antibody against Stx2 (TMA-15, 1 μg/ml, approximately
150× excess). All experiments were performed in duplicate.
To measure the transfer of Stx2 from the monocyte, the
protein synthesis of the target cells was determined by
adding
3H-Leucine (0.67 μCi/ml). Subsequently, intracel-
lular proteins were precipitated by treatment with trichloro-
acetic acid (TCA), and the radioactivity was measured in a
liquid scintillation counter. In the other experimental
setting, monocytes were loaded in a similar way with
FITC-labeled Stx1B subunit; 1×10
6-loaded monocytes
were coincubated with 1.25×10
5 vero cells in suspension
for 3 h at 4°C (n=5) while being continuously rotated. At
this temperature, bias due to internalization of the toxin
could be avoided [19, 25]. After 3 h, the presence of Stx1B
subunit FITC on the vero cells was determined by flow
cytometry. For every experiment, at least 1,000 cells were
measured.
Study of supernatant Stx-loaded monocytes
To study the effect of the supernatant of Stx2-loaded
monocytes, it was collected after 16 h of coincubation on
vero cells (n=11). The supernatants were centrifuged to
remove possible monocytes and added again to fresh vero
cells. Protein synthesis was measured by adding
3H-leucine
and measuring the incorporation after 24 h of incubation at
37°C. Also, the antibody against Stx2 was used to
determine a possible effect of free Stx2. Furthermore,
monocytes were loaded with
125I-Stx1B subunit to inves-
tigate whether it could be released after a change in
temperature from 4° to 37°C (n=3). For each experiment,
between 3 and 4×10
6 monocytes are loaded with 200 nM
Stx1B subunit (3,600 cpm/ng protein). After loading,
unbound Stx1B subunit was removed by centrifugation.
Subsequently, the monocytes were placed at 37°C for 2 h.
They were then centrifuged, and cells and supernatant were
measured separately for the presence of
125I-Stx1B with a
gamma counter. This was compared with the amount of
binding to the monocytes before the temperature change.
The experiment was performed in duplicate.
Statistics
All data presented are expressed as a range with the
median. Significance of increase or decrease of protein
synthesis compared with controls was analyzed using the
Wilcoxon signed ranks test. The statistical level of
significance was defined as P<0.05.
Fig. 1 Coincubation of Shiga-like toxin (Stx)2-loaded monocytes
with target cells [vero cells and human umbilical cord venous
endothelial cells (HUVEC)]. To investigate whether monocytes could
transfer Stx2, toxin-loaded monocytes were coincubated with vero
cells (n=9) and HUVEC (n=10). This led to protein synthesis
inhibition, as could be determined with the incorporation of
3H-
leucine. The coincubation with unloaded monocytes was used as a
control and set at 100%. ** P<0.01
Fig. 2 Effect of the addition of an antibody against Shiga-like toxin
(Stx)2. The monocytes of five healthy donors were coincubated with
vero cells (Stx2-loaded monocytes, white bar; Stx2-loaded monocytes
with Stx2 antibody, black bar). Addition of the antibody against Stx2
led to partial protein synthesis recovery in four donors and complete
recovery in one donor. Coincubation with unloaded monocytes was
used as a control and set at 100%
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Coincubation Stx2-loaded monocytes and target cells
To investigate whether monocytes can transfer Stx2 to
target cells (vero cells and HUVECs), Stx2-loaded mono-
cytes were added to a monolayer of these cells. After
coincubation, protein synthesis of vero cells and HUVEC
was measured. If the Stx2 was transferred to the target cells,
there was protein synthesis inhibition, as this is the
biological effect of Stx2 in both types of target cells. After
24 h of coincubation at 37°C, in both cell types, there was
protein synthesis inhibition (Fig. 1). In vero cells, greater
protein synthesis reduction was measured than in HUVEC.
Directly adding 10 nM Stx2 to vero cells reduced protein
synthesis to 5.5% (data not shown). When an antibody
against Stx2 was added to the monocytes before coincuba-
tion with vero cells, protein synthesis inhibition was partly
restored (Fig. 2). Only in one out of five experiments was
there complete recovery.
Fig. 3 Addition of supernatants coincubation to vero cells. After
coincubation of Shiga-like toxin (Stx)-loaded and unloaded mono-
cytes, supernatants were collected and re-added to fresh vero cells
(n=11). The supernatant from the toxin-loaded monocytes induced,
again, protein synthesis inhibition. This inhibition could be partially
restored with a Stx2 antibody (AB). The incubation of supernatant
with unloaded monocytes was used as a control and set at 100%.
** P<0.01
Table 1 Amount of
125I- Shiga-like toxin (Stx)1B subunit on cells





Vero cells 1,034,383 671,060
Monocytes donor 1 1,437 427
Monocytes donor 2 1,070 374
Monocytes donor 3 1,121 677
cpm counts per minute
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TMA-15 also partly prevented protein synthesis inhibition
(data not shown).
Study of supernatant Stx-loaded monocytes
Because the addition of an antibody against Stx2 was not
sufficient for complete protein synthesis recovery in four
out of five tested donors, we investigated the possible
presence of an additional inhibitor in the supernatant after
16 h of coincubation. This was performed by re-adding the
supernatant of coincubated Stx2-loaded monocytes and a
monolayer of vero cells to new vero cells. Figure 3 shows
that this incubation again led to an inhibitory effect on
vero-cell protein synthesis in contrast to the supernatant of
unloaded monocytes. But this reduction was less than with
direct coincubation. The effect could be partly blocked by
adding the antibody against Stx2. This means that there is
unbound Stx2 present in the supernatant. Next, we
investigated whether the temperature change of the Stx-
loaded monocytes from 4° to 37°C could lead to toxin
release. For this reason, we loaded the monocytes with
125I-
Stx1B subunit. The amount of radioactivity on or inside the
monocytes was measured before and after incubation of the
cells for 2 h at 37°C (Table 1). Vero cells were used as a
control. In vero cells as in monocytes, the toxin was
released from its receptor after the incubation.
Transfer of Stx to target cells without change in temperature
A change in temperature from 4° to 37°C released Stx from
its receptor on the monocyte. To study again the possibility
of Stx transfer from monocyte to target cells, we loaded
isolated monocytes with Stx1B subunit labeled with FITC.
Coincubation of these monocytes with vero cells in
suspension without a change in temperature did not result
in a transfer of the B subunit to the vero cells (n=5, Fig. 4).
Discussion
After coincubation of Stx2-loaded monocytes with target-
cells (vero cells and HUVEC), protein synthesis inhibition
could be detected. As the biological effect of Stx is protein
synthesis inhibition, a transfer was expected. This effect
could not be due to the presence of monocytes, because it is
well described that Stx has no inhibitory effect on
peripheral blood monocytes [17]. However, the addition
of an antibody against Stx only partly restored the
inhibition. We hypothesized that in parallel to transfer of
Stx2, a possible additional inhibiting factor was present in
Fig. 4 Transfer of Shiga-like toxin (Stx)-loaded monocytes to vero
cells without temperature shift (white: normal monocytes; black: Stx-
loaded monocytes; grey: vero cells). The x-axis represents the
intensity of the fluorescein isothiocyanate (FITC) signal, the y-axis
represents the number of cells. a FITC-labeled Stx1B subunit was
bound to monocytes from a healthy donor, showing an increase in
intensity. b Coincubation of vero cells and unloaded monocytes; note
the high basal signal of vero cells. c After 2 h of coincubation with
vero cells in suspension at 4°C, there was no transfer of the FITC
signal. The cells remained in position
Fig. 5 Schematic summary of
performed experiments. a
Monocytes loaded with Shiga-
like toxins (Stx) at 4°C. b After
shifting Stx-loaded monoytes to
target cells at 37°C, Stx was
released from its receptor. This
led to protein synthesis inhibi-
tion of target cells. However,
transport could not be excluded
(but this was performed in
experiments without a shift in
temperature). Probably, some
toxin was internalized and
monocytes became activated.
This could lead to cytokine and
proteases production (possible
cytotoxic factors). c When the
supernatant is re-added to new
target cells, there are released
Stx and secreted products pres-
ent. This induced, again, protein
synthesis inhibition
Pediatr Nephrol (2007) 22:1181–1187 1185the supernatant during the experiment. To further investi-
gate this possibility, the supernatant of this coincubation
was re-added to fresh vero cells. Again, there was protein
synthesis inhibition, which could partly be decreased by
blocking with the Stx2 antibody. The conclusion was made
that there another inhibitory factor needed to be present
(possibly released by activated monocytes), but unbound
Stx2 was also present [26]. Apparently, Stx1B subunit is
released from its receptor when there is shift of temperature
from 4° to 37°C, as shown in this study and also by
Ramegowda and Tesh [18]. This finding stresses the
caution that must be taken when drawing conclusions from
in vitro experiments performed at 4°C. In Fig. 5, all
findings are schematically summarized.
As these in vitro experiments were not suitable to
investigate a possible transfer, experiments were performed
without a change of temperature. No transfer of the binding
part of the toxin could be detected in this setting. Experi-
ments could not be performed at 37°C because the toxin is
internalized by the monocytes during 3 h of incubation.
Because of these in vitro experiments, we believe that the
monocyte cannot function as a transporter for Stx in the
circulation. However, monocytes still seem to play an
important role in pathogenesis. As a component of the
innate immune system, they play a central role in immunity
and inflammation. Fernandez et al. showed that patients in
the acute period of HUS have monocytes with phenotypic
(reduced expression of CD14, CD64, and CD11b) and
functional [decreases lipopolysaccharide (LPS)-induced
TNF-α production and Fcγ-dependent cytotoxicity] differ-
ences compared with healthy children and acute uremic
children [27].
Some unanswered questions remain. What is the
inhibitory factor released by monocytes after loading with
Stx? Why is there still unbound Stx2 present in the
supernatant after 16 h of coincubation? It is surprising that
Stx2 is not completely bound and internalized by the
numerous receptors on monocytes and vero cells. Also,
how Stx is transported in the circulation remains unsolved.
Kimura et al. described that serum amyloid P (SAP) can
bind Stx2 and function as a neutralizing factor [28].
However, in humans, there was no correlation between
circulating SAP and the development of HUS [29].
As renal endothelial damage is already present after the
occurrence of clinical symptoms of HUS, it is very
important to develop efficacious early prevention. Under-
standing the mechanism in which the toxin is specifically
targeted to the kidney can lead to novel intervention
strategies.
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